查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1607982

止血診斷市場：按產品類型、測試類型、最終用途分類 - 2025-2030 年全球預測

Hemostasis Diagnostics Market by Product (Consumables, Laboratory Analyzers, Point-of-Care Testing Systems), Test Type (Activated Clotting Time, Activated Partial Thromboplastin Time, D Dimer Test), End Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年止血診斷市值為5.7932億美元，預計到2024年將達到6.201億美元，複合年成長率為8.04%，到2030年將達到9.9577億美元。

止血診斷市場的範圍包括旨在識別和管理止血疾病的產品和服務，例如血塊形成、血小板功能和凝血因子的測試。作為醫療保健系統的關鍵組成部分，這些診斷對於診斷血友病、血栓症和其他出血性疾病等疾病至關重要。應用範圍包括醫院、診斷中心、研究機構和學術機構，最終用途範圍從個別患者診斷到大規模篩檢計畫。市場成長受到血液相關疾病日益流行、就地檢驗等技術進步以及易患此類疾病的老年人口增加的影響。開發和部署新的診斷技術（例如基於人工智慧的資料分析和個人化醫療方法）存在商機，以提高診斷的速度和準確性。公司應該探索與生物技術公司和醫療保健提供者的合作夥伴關係，以利用這些進步。然而，與診斷工具相關的高成本和複雜的監管要求等挑戰可能會阻礙市場擴張。發展中地區的能見度有限和基礎設施不足進一步凸顯了潛在的成長障礙。為了最大限度地發揮成長潛力，公司應該專注於創新，例如提高現有測試的靈敏度和特異性或設計可提供快速可靠結果的攜帶式診斷設備。與學術機構合作進行前沿研究以及利用巨量資料來提高診斷準確性是利用這些機會的基本策略。競爭的市場格局是動態的，需要適應性策略來應對監管環境和技術轉變，因此保持競爭優勢並滿足不斷變化的醫療保健需求需要採取積極主動的方法。

主要市場統計
基準年[2023] 57932萬美元
預計年份 [2024] 6.201 億美元
預測年份 [2030] 9.9577 億美元
複合年成長率（%） 8.04%

市場動態：快速發展的止血診斷市場的關鍵市場洞察

供需的動態交互作用正在改變止血診斷市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球止血疾病增加
    • 傾向於就地檢驗解決方案
    • 提高對止血疾病的認知並重視早期診斷
  • 市場限制因素
    • 診斷成本上升和產品召回
  • 市場機會
    • 透過個人化醫療實現個人化治療
    • 止血診斷方法的進展
  • 市場挑戰
    • 止血診斷的複雜測試方法

波特五力：開拓止血診斷市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對止血診斷市場的影響

外部宏觀環境因素在塑造止血診斷市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解止血診斷市場的競爭狀況

對止血診斷市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣止血診斷市場廠商績效評估

FPNV定位矩陣是評估止血診斷市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪止血診斷市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，止血診斷市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球止血疾病的發生率增加
      • 就地檢驗解決方案的趨勢
      • 提高對止血疾病的認知以及早期診斷的重要性
    • 抑制因素
      • 高診斷成本和產品召回率
    • 機會
      • 利用個人化醫療方法為患者提供量身訂製的治療
      • 止血診斷方法的進展
    • 任務
      • 止血診斷的複雜測試方法
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章止血診斷市場：依產品

  • 消耗品
  • 實驗室分析儀
  • 就地檢驗系統

第7章按測試類型分類的止血診斷市場

  • 活化凝血時間
  • 活化部份凝血活酵素時間
  • D-二聚體測試
  • 纖維蛋白原測試
  • 血小板凝集試驗
  • 凝血酶原時間（PT）測試

第8章止血診斷市場：依最終用途

  • 居家照護環境
  • 醫院/診所
  • 獨立診斷實驗室

第9章 北美、南美止血診斷藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太止血診斷市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章：歐洲、中東和非洲止血診斷市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • ARUP Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Danaher Corporation
  • DiaPharma Group, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Grifols, SA
  • Haemonetics Corporation
  • Helena Laboratories Corporation
  • HemoSonics, LLC
  • HORIBA Group
  • Laboratory Corporation of America Holdings
  • Medtronic PLC
  • Merck & Co., Inc.
  • Randox Laboratories Ltd.
  • Siemens AG
  • Stago Group
  • Sysmex America, Inc.
  • Sysmex Europe SE
  • Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH
  • Thermo Fisher Scientific Inc.
  • Werfen, SA
Product Code: MRR-DD0700E81E58

The Hemostasis Diagnostics Market was valued at USD 579.32 million in 2023, expected to reach USD 620.10 million in 2024, and is projected to grow at a CAGR of 8.04%, to USD 995.77 million by 2030.

The scope of the hemostasis diagnostics market encompasses products and services aimed at identifying and managing hemostatic disorders, including tests for blood clot formation, platelet function, and coagulation factors. As critical components of the healthcare system, these diagnostics are vital for diagnosing conditions such as hemophilia, thrombosis, and other bleeding disorders. Their applications extend across hospitals, diagnostic centers, research institutions, and academic settings, with an end-use scope that includes individual patient diagnostics and large-scale screening programs. Market growth is influenced by an increasing prevalence of blood-related disorders, advancements in technology like point-of-care testing, and a growing geriatric population susceptible to such conditions. Opportunities exist in the development and deployment of novel diagnostic technologies, such as AI-driven data analysis and personalized medicine approaches, to enhance diagnostic speed and accuracy. Businesses should explore collaborations with biotechnology firms and healthcare providers to leverage these advancements. However, challenges including high costs associated with diagnostic tools and complex regulatory requirements can impede market expansion. Limitations in awareness and inadequate infrastructure in developing regions further stress potential growth barriers. To maximize growth potential, companies could focus on innovations like improving the sensitivity and specificity of existing tests, or devising portable diagnostic devices that offer rapid, reliable results. Collaboration with academic institutions for cutting-edge research and leveraging big data to refine diagnostic precision are vital strategies for capitalizing on these opportunities. The nature of the hemostasis diagnostics market is dynamic and requires adaptive strategies to navigate regulatory landscapes and technological shifts, necessitating forward-thinking approaches to maintain competitive advantage and meet evolving healthcare needs.

KEY MARKET STATISTICS
Base Year [2023] USD 579.32 million
Estimated Year [2024] USD 620.10 million
Forecast Year [2030] USD 995.77 million
CAGR (%) 8.04%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hemostasis Diagnostics Market

The Hemostasis Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increase in incidences of hemostasis disorders worlwide
    • Inclination toward point-of-care testing solutions
    • Growing awareness of hemostasis disorders and emphasis on early diagnosis
  • Market Restraints
    • High cost of diagnosis and incidences of product recall
  • Market Opportunities
    • Utilization of personalized medicine approach to deliver tailored treatments
    • Advancements in diagnostic methods for hemostasis
  • Market Challenges
    • Complex testing methods for hemostasis diagnosis

Porter's Five Forces: A Strategic Tool for Navigating the Hemostasis Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hemostasis Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hemostasis Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hemostasis Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hemostasis Diagnostics Market

A detailed market share analysis in the Hemostasis Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hemostasis Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hemostasis Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hemostasis Diagnostics Market

A strategic analysis of the Hemostasis Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hemostasis Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, ARUP Laboratories, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., bioMerieux SA, Danaher Corporation, DiaPharma Group, Inc., F. Hoffmann-La Roche Ltd., Grifols, S.A., Haemonetics Corporation, Helena Laboratories Corporation, HemoSonics, LLC, HORIBA Group, Laboratory Corporation of America Holdings, Medtronic PLC, Merck & Co., Inc., Randox Laboratories Ltd., Siemens AG, Stago Group, Sysmex America, Inc., Sysmex Europe SE, Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH, Thermo Fisher Scientific Inc., and Werfen, S.A..

Market Segmentation & Coverage

This research report categorizes the Hemostasis Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Consumables, Laboratory Analyzers, and Point-of-Care Testing Systems.
  • Based on Test Type, market is studied across Activated Clotting Time, Activated Partial Thromboplastin Time, D Dimer Test, Fibrinogen Test, Platelet Aggregation Test, and Prothrombin Time (PT) Test.
  • Based on End Use, market is studied across Home Care Setting, Hospitals/Clinics, and Independent Diagnostic Laboratories.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in incidences of hemostasis disorders worlwide
      • 5.1.1.2. Inclination toward point-of-care testing solutions
      • 5.1.1.3. Growing awareness of hemostasis disorders and emphasis on early diagnosis
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of diagnosis and incidences of product recall
    • 5.1.3. Opportunities
      • 5.1.3.1. Utilization of personalized medicine approach to deliver tailored treatments
      • 5.1.3.2. Advancements in diagnostic methods for hemostasis
    • 5.1.4. Challenges
      • 5.1.4.1. Complex testing methods for hemostasis diagnosis
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Hemostasis Diagnostics Market, by Product

  • 6.1. Introduction
  • 6.2. Consumables
  • 6.3. Laboratory Analyzers
  • 6.4. Point-of-Care Testing Systems

7. Hemostasis Diagnostics Market, by Test Type

  • 7.1. Introduction
  • 7.2. Activated Clotting Time
  • 7.3. Activated Partial Thromboplastin Time
  • 7.4. D Dimer Test
  • 7.5. Fibrinogen Test
  • 7.6. Platelet Aggregation Test
  • 7.7. Prothrombin Time (PT) Test

8. Hemostasis Diagnostics Market, by End Use

  • 8.1. Introduction
  • 8.2. Home Care Setting
  • 8.3. Hospitals/Clinics
  • 8.4. Independent Diagnostic Laboratories

9. Americas Hemostasis Diagnostics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Hemostasis Diagnostics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Hemostasis Diagnostics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. ARUP Laboratories
  • 3. Becton, Dickinson and Company
  • 4. Bio-Rad Laboratories, Inc.
  • 5. bioMerieux SA
  • 6. Danaher Corporation
  • 7. DiaPharma Group, Inc.
  • 8. F. Hoffmann-La Roche Ltd.
  • 9. Grifols, S.A.
  • 10. Haemonetics Corporation
  • 11. Helena Laboratories Corporation
  • 12. HemoSonics, LLC
  • 13. HORIBA Group
  • 14. Laboratory Corporation of America Holdings
  • 15. Medtronic PLC
  • 16. Merck & Co., Inc.
  • 17. Randox Laboratories Ltd.
  • 18. Siemens AG
  • 19. Stago Group
  • 20. Sysmex America, Inc.
  • 21. Sysmex Europe SE
  • 22. Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH
  • 23. Thermo Fisher Scientific Inc.
  • 24. Werfen, S.A.

LIST OF FIGURES

  • FIGURE 1. HEMOSTASIS DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. HEMOSTASIS DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. HEMOSTASIS DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. HEMOSTASIS DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HEMOSTASIS DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HEMOSTASIS DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY LABORATORY ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY ACTIVATED CLOTTING TIME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY ACTIVATED PARTIAL THROMBOPLASTIN TIME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY D DIMER TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY FIBRINOGEN TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PLATELET AGGREGATION TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PROTHROMBIN TIME (PT) TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY HOSPITALS/CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY INDEPENDENT DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 149. HEMOSTASIS DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 150. HEMOSTASIS DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023